4-(4-METHOXYPHENYL)-6-(3,4,5-TRIMETHOXYPHENYL)-3,4-DIHYDROPYRIMIDINE-2(1H)-THIONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LCVIXCCSXDDQAT-UHFFFAOYSA-N
Smiles	COc1ccc(cc1)C2NC(=S)NC(=C2)c3cc(OC)c(OC)c(OC)c3
InChI	InChI=1S/C20H22N2O4S/c1-23-14-7-5-12(6-8-14)15-11-16(22-20(27)21-15)13-9-17(24-2)19(26-4)18(10-13)25-3/h5-11,15H,1-4H3,(H2,21,22,27)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H22N2O4S
Molecular Weight	386.46
AlogP	3.71
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	6.0
Polar Surface Area	93.07
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	27.0

Assay Description	Organism	Bioactivity
Cytotoxicity against Mus musculus (mouse) B16 cells after 72 hr by MTT assay	Mus musculus	36000.0 nM
Cytotoxicity against Mus musculus (mouse) L1210 cells after 72 hr by MTT assay	Mus musculus	41000.0 nM
Antiprotozoan activity against Giardia intestinalis after 72 hr by MTT assay	Giardia intestinalis	22300.0 nM
Antiprotozoan activity against Plasmodium falciparum assessed as inhibition of [3H]hypoxanthine incorporation incubated for 24 hr prior to [3H]hypoxanthine addition measured after 18 hr by liquid scintillation counting	Plasmodium falciparum	14500.0 nM
Antiprotozoan activity against Trypanosoma lewisi after 72 hr by MTT assay	Trypanosoma lewisi	17900.0 nM
Antiprotozoan activity against Leishmania tarentolae after 72 hr by MTT assay	Leishmania tarentolae	12500.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2262110
PubChem	76312181

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).